We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

4543:TSETerumo Corporation Analysis

Data as of 2026-03-13 - not real-time

¥2,071.50

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

Terumo Corp. is trading at ¥2,071.5, well above its DCF‑derived fair value of ¥998.5, indicating a significant premium. Technical indicators show a bearish bias: the price sits below the 20‑day (¥2,012.6) and 50‑day (¥2,099.0) SMAs and the 200‑day SMA (¥2,424.9), while the trend direction is flagged as bearish and volume is decreasing. The RSI of 52.6 suggests neutral momentum, and although the MACD histogram is positive, the MACD line remains below the signal, reinforcing a short‑term pull‑back risk. Volatility is high at 34% over the past 30 days, yet beta is modest (0.45), implying the stock moves less than the broader market despite price swings. On the fundamentals side, revenue grew 12.6% year‑over‑year to ¥1.10 trillion, with solid gross (53.3%) and operating margins (14.8%). Earnings per share are rising (trailing EPS ¥88.53, forward EPS ¥101.83) and the forward PE of 20.3 is below the current 23.4, hinting at improving valuation. The company generates strong cash flow (operating cash flow ¥208.5 bn) and maintains a healthy dividend yield of 1.47% with a payout ratio of 31.6%, supporting dividend sustainability. Analyst consensus is a “Buy” with a mean target price near ¥2,956, suggesting expectations of further upside despite current overvaluation. The balance sheet shows ample cash (¥238 bn) but high debt (¥449 bn) leading to a debt‑to‑equity of 29.5, which warrants monitoring. Overall, the stock presents a mixed picture of short‑term technical weakness against a backdrop of robust fundamentals and dividend appeal.
Given the premium valuation, high volatility, and bearish technicals, investors may prefer a cautious stance in the near term while recognizing the company’s strong growth drivers, diversified global footprint, and reliable dividend stream that support a longer‑term buy case.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price below key moving averages and bearish trend direction
  • Decreasing volume and proximity to resistance level
  • Neutral RSI with modest MACD divergence

Medium Term

1–3 years
Neutral
Model confidence: 7/10

Key Factors

  • Strong revenue growth and expanding operating margins
  • Solid cash generation and sustainable dividend payout
  • Forward PE compression relative to current PE

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • Diversified global product portfolio in medical devices
  • Consistent dividend track record with low payout ratio
  • Robust free cash flow supporting reinvestment and debt reduction

Key Metrics & Analysis

Financial Health

Revenue Growth12.60%
Profit Margin11.68%
P/E Ratio23.4
ROE8.74%
ROA5.87%
Debt/Equity29.47
P/B Ratio2.0
Op. Cash Flow¥208.5B
Free Cash Flow¥72.3B
Industry P/E26.3

Technical Analysis

TrendBearish
RSI52.6
Support¥1,900.00
Resistance¥2,110.00
MA 20¥2,012.60
MA 50¥2,099.01
MA 200¥2,424.96
MACDBullish
VolumeDecreasing
Fear & Greed Index73.45

Valuation

Fair Value¥998.55
Target Price¥2,956.15
Upside/Downside42.71%
GradeOvervalued
TypeBlend
Dividend Yield1.47%

Risk Assessment

Beta0.45
Volatility34.35%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.